CMR Naviscan Adds Gamma Medica Molecular Breast Imaging (MBI) Technology to Complement its Breast PET Imaging (BPI) Solutions

CMR Naviscan Corporation has acquired certain Gamma Medica (GM) assets and intellectual property. This acquisition positions CMR Naviscan to provide a comprehensive solution for the diagnosis and care of breast cancer patients.

CARLSBAD, CA (PRWEB) October 06, 2017

CMR Naviscan Corporation announces that it has acquired certain Gamma Medica (GM) assets and intellectual property. The GM Molecular Breast Imaging (MBI) technology, including the LumaGEM® MBI scanner complements the existing CMR Naviscan organ-specific positron emission tomography (PET) product portfolio, including its Solo II® Breast PET Imaging (BPI) system, positioning CMR Naviscan as a comprehensive solutions provider to the diagnosis and care of breast cancer patients.

"With the addition of this Molecular Breast Imaging technology, we are now able to offer healthcare providers a more comprehensive portfolio of screening and problem solving tools for the care of breast cancer patients, including secondary screening of dense breasts, image-guided biopsy, surgical planning, and treatment monitoring," said Tonatiuh Monroy, CMR Naviscan's President.

The value of MBI in the patient care continuum is detailed in the recently published article, Molecular Breast Imaging in Breast Cancer Screening and Problem Solving, (RadioGraphics 2017:37:1309-1327; https://doi.org/10.1148/rg.2017160204). Furthermore, with guidance on MBI as appropriate radiologic care, American College of Radiology (ACR) Practice Parameter, published in July, (https://www.acr.org/~/media/ACR/Documents/PGTS/guidelines/MBI.pdf?db=web), the role of the technology is becoming a standard of care. By adding MBI to its suite of solutions, CMR Naviscan continues on its path as a leader in molecular imaging and problem solving.

Please visit CMR Naviscan at the 2017 Annual Meeting of the Radiological Society of North America (RSNA), November 26 – 30, to learn more of the tools and solutions now available. We will be located as part of the Compañia Mexicana de Radiologia (CMR) exhibit, located at Booth #2941, McCormick Place, Chicago.

About CMR Naviscan Corporation

CMR Naviscan is a leader in organ-specific molecular imaging and part of the Compañia Mexicana de Radiologia CGR, S.A. de C.V. (CMR), a global developer and manufacturer of high quality diagnostic imaging equipment and healthcare information systems, including DICOM-compliant imaging software. CMR Naviscan, headquartered in Carlsbad, California, develops and manufactures molecular imaging systems, including the Solo II™ High Resolution Breast PET Imaging (BPI) scanner, which detects breast cancers as small as 1.6 mm, the Stereo Navigator PET-guided biopsy tool, and the LumaGEM dual-head molecular breast imaging (MBI) system. CMR Naviscan is US FDA registered and ISO 13485:2012 certified. For more information visit http://www.cmr-naviscan.com/.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/10/prweb14761936.htm